Retrospective analyses for any potential association(s) between this subset and patient responsiveness to dual PD-1 and LAG-3 blockade could be undertaken to determine the exploratory biomarker potential of this subset (as was recently shown for PD-1high CD8 T cells from NSCLC (48)) and complement experimental efforts to determine whether this subset is a primary mechanistic target of dual blockade. This evidence concerns the gene LAG3 and non-small cell lung carcinoma.